(Q39548378)

13 September 2017

title

Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats (English)

1 reference

13 September 2017

1 reference

9

Michael Bachmann

1 reference

13 September 2017

7

Achim Temme

1 reference

13 September 2017

1

Anja Feldmann

1 reference

13 September 2017

2

Slava Stamova

1 reference

13 September 2017

3

Claudia C Bippes

1 reference

13 September 2017

5

Rebekka Wehner

1 reference

13 September 2017

Holger Bartsch

4

1 reference

13 September 2017

Marc Schmitz

series ordinal

6

1 reference

13 September 2017

Marc Cartellieri

series ordinal

8

1 reference

13 September 2017

publication date

28 December 2010

1 reference

13 September 2017

1 reference

13 September 2017

volume

71

1 reference

13 September 2017

issue

9

1 reference

13 September 2017

page(s)

998-1011

1 reference

13 September 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Androgen deprivation therapy for prostate cancer: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Monoclonal antibody-based therapeutics for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Antibody-based therapeutics: focus on prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Engineering bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Bispecific and bifunctional single chain recombinant antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Advances in specific immunotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Prostate stem cell antigen: a prospective therapeutic and diagnostic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Identification of La ribonucleoproteins as a component of interchromatin granules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

Generation of bispecific and tandem diabodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21315

21 January 2018

Identifiers

DOI

10.1002/PROS.21315

1 reference

13 September 2017

1 reference